Clinical trials: Healthy Control Subjects
Healthy
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
The purpose of this study is to investigate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06372865 for 14 days in healthy subjects of two age groups, 18-55 years (Group 1) and 56-75 years…
- Trial name
- NCT02070289
- Testing
- PF-06372865
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will be the first administration of CCI15106 capsules for inhalation to humans. The primary objective of the study is to investigate the safety and tolerability of single and repeat escalating doses of CCI15106 in…
- Trial name
- NCT03243760
- Testing
- CCI15106 7.5 mg capsule
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Safety, Peripheral Neuropathy
Xanamem™ in Healthy Elderly Subjects
Xanamem™ is being developed as a potential drug for Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body.
- Conditions
- Safety, Peripheral Neuropathy, Cortisol, Central Nervous System
- Trial name
- XanaHES (NCT03830762)
- Testing
- Xanamem
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Actinogen Medical
Healthy Subjects
First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders
The primary purpose of this first-in-man study is to investigate whether a new drug for neurological disorders is safe and well-tolerated when administered orally to healthy male adults
- Trial name
- NCT02719197
- Testing
- AC-083
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Sleep Deprivation
Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss
This is a double-blind, single center, parallel group, placebo and active comparator, controlled study to characterize the wake promoting effects of single doses of SPD489 in healthy adult male undergoing acute sleep deprivation.
- Trial name
- NCT01096680
- Testing
- SPD489 20 mg, SPD489 50 mg, SPD489 70 mg
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Shire
Metabolic Syndrome, Obesity
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single oral dose.
- Trial name
- NCT01285388
- Testing
- MB12066
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Asthma
Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.
To evaluate the safety and tolerability of S-1226 composed of perflubron with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered over 2 minute nebulisation to healthy subjects.
- Trial name
- NCT02616770
- Testing
- S1226 (4%), Saline (for 4%), S1226(8%)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SolAeroMed Inc.
Healthy Volunteers
A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06266047 after first-time administration to healthy adult subjects.
- Trial name
- NCT02539550
- Testing
- PF-06266047
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects (HS)
To Evaluate the Effect of Bacillus Coagulans Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults
This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the effects of a Bacillus coagulans-based probiotic product on gut health, immunological parameters, and overall tolerability in healthy…
- Trial name
- NCT07377994
- Testing
- Probiotic (Bacillus Coagulans)
- Where
- India
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bioagile Therapeutics Pvt. Ltd.
Healthy Subjects
Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine
Several combinations of H5N1 antigen concentrations and aluminium-hydroxide adjuvant concentrations will be tested for their safety and capacity to induce a specific immune response.
- Trial name
- NCT00562237
- Testing
- S205 10ugHA, S205 30ugHA, S205 10ugHA+500ugAlOH
- Where
- 6 sites in Finland, Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Influenza
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old
This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in the EU and many other worldwide…
- Trial name
- NCT00464672
- Testing
- Influenza virus vaccine, Comparator influenza vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Novartis
Schizophrenia
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
- Trial name
- NCT01900522
- Testing
- ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Takeda
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc)
- Trial name
- NCT06037577
- Testing
- CM-101
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ChemomAb Ltd.
Healthy Volunteers
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
The objective of this study is to assess the safety, tolerability, pharmacokinetics and immunogenicity of either single ascending intravenous (IV) doses of ABBV-243 or single ascending subcutaneous (SC) doses of ABBV-243 in…
- Trial name
- NCT07306754
- Testing
- ABBV-243
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple repeat oral doses of PF-06372865 in healthy adult subjects.
- Trial name
- NCT03351751
- Testing
- PF-06372865
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Painful Osteoarthritis of the Knee
Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers
This study will evaluate safety, tolerability, pharmacokinetics and immunogenicity of MEDI7352 in healthy participants.
- Trial name
- NCT04770428
- Testing
- MEDI7352
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Parkinson Disease, Healthy
Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects
The purpose of this study is to investigate effects of foliglurax on brain wave patterns (electric signals) in healthy subjects and in patients with PD
- Trial name
- NCT04322227
- Testing
- Foliglurax 10 mg (treatment A), Foliglurax 30 mg (treatment B)
- Where
- France
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Metabolic Disease
Safety, Tolerability and PK of PXL770 in Healthy Male Subjects
PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03395470
- Testing
- PXL770, Rosuvastatin
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Poxel SA
Healthy
A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects
The purpose of this trial is to to investigate the safety of LEO 90105 compared with its vehicle after multiple administration (twice daily, 5 days) in healthy Japanese male subjects.
- Trial name
- NCT01293383
- Testing
- LEO 90105
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Cognitive Disorders
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
- Trial name
- NCT02342041
- Testing
- SUVN-G3031
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited